{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:59:21Z","timestamp":1770742761142,"version":"3.49.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p><jats:italic>Staphylococcus aureus<\/jats:italic> poses a significant threat as an opportunistic pathogen in humans, and animal medicine, particularly in the context of hospital-acquired infections (HAIs). Effective treatment is a significant challenge, contributing substantially to the global health burden. While antibiotic therapy remains the primary approach for staphylococcal infections, its efficacy is often compromised by the emergence of resistant strains and biofilm formation. The anticipated solution is the discovery and development of new antibacterial agents. However, this is a time consuming and expensive process with limited success rates. One potential alternative for addressing this challenge is the repurposing of existing antibiotics. This study investigated the potential of rifabutin (RFB) as a repurposed antibiotic for treating <jats:italic>S. aureus<\/jats:italic> infections. The minimum inhibitory concentration (MIC) of rifabutin was assessed by the broth microdilution method, in parallel to vancomycin, against 114 clinical isolates in planktonic form. The minimum biofilm inhibitory concentration (MBIC<jats:sub>50<\/jats:sub>) was determined by an adaptation of the broth microdilution method, followed by MTT assay, against a subset of selected 40 clinical isolates organized in biofilms. The study demonstrated that RFB MIC ranged from 0.002 to 6.250\u2009\u03bcg\/mL with a MIC<jats:sub>50<\/jats:sub> of 0.013\u2009\u03bcg\/mL. RFB also demonstrated high anti-biofilm activity in the subset of 40 clinical isolates, with confirmed biofilm formation, with no significant MBIC<jats:sub>50<\/jats:sub> differences observed between the MSSA and MRSA strains, in contrast to that observed for the VAN. These results highlight the promising efficacy of RFB against staphylococcal clinical isolates with different resistance patterns, whether in planktonic and biofilm forms.<\/jats:p>","DOI":"10.3389\/fmicb.2024.1475124","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T12:19:57Z","timestamp":1728562797000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Rifabutin: a repurposed antibiotic with high potential against planktonic and biofilm staphylococcal clinical isolates"],"prefix":"10.3389","volume":"15","author":[{"given":"Magda","family":"Ferreira","sequence":"first","affiliation":[]},{"given":"Margarida","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Frederico","family":"Aires-da-Silva","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Bettencourt","sequence":"additional","affiliation":[]},{"given":"Maria Manuela","family":"Gaspar","sequence":"additional","affiliation":[]},{"given":"Sandra Isabel","family":"Aguiar","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00959-19","article-title":"In vitro activity of rifampin, rifabutin, rifapentine, and rifaximin against planktonic and biofilm states of staphylococci isolated from periprosthetic joint infection","volume":"63","author":"Albano","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e0233284","DOI":"10.1371\/journal.pone.0233284","article-title":"Vancomycin and nisin a are effective against biofilms of multi-drug resistant Staphylococcus aureus isolates from human milk","volume":"15","author":"Angelopoulou","year":"2020","journal-title":"PLoS One"},{"key":"ref3","first-page":"132","article-title":"Rifamycins","volume-title":"Meyler\u2019s Side Effects of Drugs","author":"Aronson","year":"2016"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.bjp.2016.08.008","article-title":"Anti-biofilm activity against Staphylococcus aureus MRSA and MSSA of neolignans and extract of Piper regnellii","volume":"27","author":"Brambilla","year":"2017","journal-title":"Rev. Bras"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/978-1-62703-664-1_12","article-title":"Investigation of biofilm formation in clinical isolates of staphylococcus aureus","volume":"1085","author":"Cassat","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1093\/infdis\/jiaa403","article-title":"Rifabutin to the rescue?","volume":"222","author":"Chambers","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref7","year":"2020"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1093\/jac\/dkw024","article-title":"Rifabutin: where do we stand in 2016?","volume":"71","author":"Crabol","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1473-3099(15)00466-1","article-title":"Alternatives to antibiotics-a pipeline portfolio review","volume":"16","author":"Czaplewski","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13756-019-0533-3","article-title":"Antibiotics versus biofilm: an emerging battleground in microbial communities","volume":"8","author":"Divakar","year":"2019","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3201\/eid0809.020063","article-title":"Biofilms: microbial life on surfaces","volume":"8","author":"Donlan","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3390\/antibiotics9060326","article-title":"Rifabutin use in Staphylococcus biofilm infections: a case series","volume":"9","author":"Doub","year":"2020","journal-title":"Antibiotics"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.1016\/j.jcot.2019.10.002","article-title":"Effects of powdered rifampin and vancomycin solutions on biofilm production of staphylococcus aureus on orthopedic implants","volume":"11","author":"Douthit","year":"2020","journal-title":"J. Clin. Orthopaed. Trauma"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s13346-020-00791-8","article-title":"Lipid-based nanosystems for targeting bone implant-associated infections: current approaches and future endeavors","volume":"11","author":"Ferreira","year":"","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.3390\/molecules26072047","article-title":"Liposomes as antibiotic delivery systems: a promising Nanotechnological strategy against antimicrobial resistance","volume":"26","author":"Ferreira","year":"","journal-title":"Molecules"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/pharmaceutics13030321","article-title":"Liposomes as a Nanoplatform to improve the delivery of antibiotics into Staphylococcus aureus biofilms","volume":"13","author":"Ferreira","year":"","journal-title":"Pharmaceutics"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ijpharm.2017.08.089","article-title":"Levofloxacin-loaded bone cement delivery system: highly effective against intracellular bacteria and Staphylococcus aureus biofilms","volume":"532","author":"Ferreira","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"7945","DOI":"10.1128\/JB.00858-07","article-title":"The EPS matrix: the \"house of biofilm cells\"","volume":"189","author":"Flemming","year":"2007","journal-title":"J. Bacteriol."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nrmicro2415","article-title":"The biofilm matrix","volume":"8","author":"Flemming","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2807\/1560-7917.ES.2021.26.46.2002094","article-title":"Staphylococcus aureus bloodstream infections: diverging trends of meticillin-resistant and meticillin-susceptible isolates, EU\/EEA, 2005 to 2018","volume":"26","author":"Gagliotti","year":"2021","journal-title":"Eur. Secur."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2174\/156802608783955629","article-title":"Developments on drug delivery systems for the treatment of mycobacterial infections","volume":"8","author":"Gaspar","year":"","journal-title":"Curr. Top. Med. Chem."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijantimicag.2007.08.008","article-title":"Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis","volume":"31","author":"Gaspar","year":"","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pathogens10010015","article-title":"Rifabutin for the treatment of helicobacter pylori infection: a review","volume":"10","author":"Gisbert","year":"2021","journal-title":"Pathogens"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrmicro821","article-title":"Bacterial biofilms: from the natural environment to infectious diseases","volume":"2","author":"Hall-Stoodley","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13054-017-1801-3","article-title":"Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment","volume":"21","author":"Hassoun","year":"2017","journal-title":"Crit. Care"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"7602","DOI":"10.3390\/ijerph18147602","article-title":"Staphylococcus aureus biofilm: morphology, genetics, pathogenesis and treatment strategies","volume":"18","author":"Idrees","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1128\/AAC.49.6.2467-2473.2005","article-title":"Use of confocal microscopy to analyze the rate of vancomycin penetration through Staphylococcus aureus biofilms","volume":"49","author":"Jefferson","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3390\/pathogens11121420","article-title":"Drug repurposing approaches towards defeating multidrug-resistant gram-negative pathogens: novel Polymyxin\/non-antibiotic combinations","volume":"11","author":"Jing","year":"2022","journal-title":"Pathogens"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/infdis\/jiaa401","article-title":"Novel use of Rifabutin and Rifapentine to treat methicillin-resistant Staphylococcus aureus in a rat model of foreign body osteomyelitis","volume":"222","author":"Karau","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref30","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1128\/9781683670131.ch45","article-title":"Staphylococcus aureus colonization of the human nose and interaction with other microbiome members","volume-title":"Gram-Positive Pathogens","author":"Laux","year":"2019"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/msphere.00920-21","article-title":"In vitro activity of Rifabutin and rifampin against antibiotic-resistant Acinetobacter baumannii, Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae","volume":"6","author":"Lee","year":"2021","journal-title":"mSphere"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.33073\/PJM-2021-005","article-title":"Epidemiology and pathogenesis of staphylococcus bloodstream infections in humans: a review","volume":"70","author":"Lisowska-\u0141ysiak","year":"2021","journal-title":"Pol. J. Microbiol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.7150\/thno.56205","article-title":"Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/spectrum.00384-22","article-title":"A case series of Rifabutin use in staphylococcal prosthetic infections","volume":"10","author":"Monk","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/antibiotics12010012","article-title":"A review of biofilm formation of Staphylococcus aureus and its regulation mechanism","volume":"12","author":"Peng","year":"2022","journal-title":"Antibiotics"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ijpharm.2016.09.074","article-title":"Can Sophorolipids prevent biofilm formation on silicone catheter tubes?","volume":"513","author":"Pontes","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/jac\/dkn513","article-title":"Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus","volume":"63","author":"Rose","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref38","first-page":"1","article-title":"Rifabutin","volume-title":"xPharm: The Comprehensive Pharmacology Reference","author":"Scholar","year":"2007"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/jac\/dkq037","article-title":"Editorial: assessing the antimicrobial susceptibility of bacteria obtained from animals","volume":"65","author":"Schwarz","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref40","first-page":"107","article-title":"Vancomycin resistance in Staphylococcus aureus strains","volume":"90","author":"Shajari","year":"2017","journal-title":"Archiv. Razi Instit."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1067284","DOI":"10.3389\/fmicb.2022.1067284","article-title":"MRSA compendium of epidemiology, transmission, pathophysiology, treatment, and prevention within one health framework","volume":"13","author":"Shoaib","year":"2023","journal-title":"Front. Microbiol."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/jac\/dkq257","article-title":"Penetration of antibiotics through Staphylococcus aureus and Staphylococcus epidermidis biofilms","volume":"65","author":"Singh","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0167-7012(00)00122-6","article-title":"A modified microtiter-plate test for quantification of staphylococcal biofilm formation","volume":"40","author":"Stepanovic","year":"2000","journal-title":"J. Microbiol. Methods"},{"key":"ref44","volume-title":"Staphylococcus aureus infection","author":"Taylor","year":"2023"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/jac\/dkab486","article-title":"Rifabutin versus rifampicin bactericidal and antibiofilm activities against clinical strains of Staphylococcus spp. isolated from bone and joint infections","volume":"77","author":"Thill","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antibiotics12010087","article-title":"Antimicrobial treatment of Staphylococcus aureus biofilms","volume":"12","author":"Tuon","year":"2023","journal-title":"Antibiotics"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref49","year":"2022"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1475124\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T12:20:14Z","timestamp":1728562814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1475124\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":49,"alternative-id":["10.3389\/fmicb.2024.1475124"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2024.1475124","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"article-number":"1475124"}}